These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34408793)

  • 21. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Toxicity of Androgen Deprivation Therapy.
    Boland J; Choi W; Lee M; Lin J
    Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Tutrone R; Saad F; George DJ; Tombal B; Bailen JL; Cookson MS; Saltzstein DR; Hanson S; Brown B; Lu S; Fallick M; Shore ND
    Eur Urol Oncol; 2024 Aug; 7(4):906-913. PubMed ID: 38143206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
    Adekunle OA; Seoane-Vazquez E; Brown LM
    J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
    Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
    George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
    Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective.
    Thorley J; Stephen S
    J Adv Pract Oncol; 2024 Jan; 15(1):43-55. PubMed ID: 39119081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
    J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
    Arjona Ferreira JC; Migoya E
    F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
    Rick FG; Schally AV
    Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does Exist a Differential Impact of Degarelix
    Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
    Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.
    Saad F; George DJ; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Tombal B; Shore ND
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835548
    [No Abstract]   [Full Text] [Related]  

  • 33. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
    Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP
    Front Oncol; 2023; 13():1289249. PubMed ID: 37916156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
    Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
    JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testosterone recovery after androgen deprivation therapy.
    Ho AY; Li EV; Bennett R; Suk-Ouichai C; Kumar SKSR; Neill C; Li Y; Schaeffer EM; Morgans AK; Patel HD; Ross AE
    Urol Oncol; 2025 Jan; 43(1):65.e1-65.e8. PubMed ID: 39242300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.